Aleff Ferreira Francisco

Aleff Ferreira Francisco

Auto-generated profile, based on publicly available information

Aleff Ferreira Francisco

Laboratório de Biotecnologia de Proteínas e Educação Aplicados à Saúde Única - LABIOPROT, Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho-RO, Brazil; Rede Internacional de Pesquisa e Conhecimento de Excelência da Amazônia Ocidental/Oriental (RED-CONEXAO), Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Biochimie
Verified
Journal Article
Closed access
GMGracianny Gomes Martins
Gracianny Gomes Martins
RHRudson de Jesus Holanda
Rudson de Jesus Holanda
JAJorge Javier Alfonso
Jorge Javier Alfonso
AGAna Fidelina Gómez Garay
Ana Fidelina Gómez Garay
ASAna Paula de Azevedo dos Santos
Ana Paula de Azevedo dos Santos
ASAndreimar Soares
Andreimar Soares

19 July 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MSMarcela C. S. Silva
Marcela C. S. Silva
SPSoraya S. Pereira
Soraya S. Pereira
MGMarilia P. Gouveia
Marilia P. Gouveia
MLMarcos B. Luiz
Marcos B. Luiz
RSRosa Maria de Oliveira Sousa
Rosa Maria de Oliveira Sousa
CFCarla Fernandes
Carla Fernandes
In order to address the global antivenom crisis, novel antivenoms need to present high therapeutic efficacy, broad neutralization ability against systemic and local damage, sufficient safety, and cost‐effectiveness. Due to biological characteristics of camelid single‐domain antibodies (VHH) such as high affinity, their ability to penetrate dense tissues, and facility for genetic manipulation, their application in antivenoms has expanded considerably. VHHs that are active against the metalloprotease BjussuMP‐II from the snake Bothrops jararacussu were selected. After isolation of BjussuMP‐II, a camelid was immunized with the purified toxin in order to construct the recombinant phage library. Following a round of biopanning, 52% of the selected clones were able to recognize BjussuMP‐II in an ELISA assay. After sequencing, seven sequence profiles were identified. One selected clone (VHH61) showed cross‐reactivity to B. brazili venom, but did not recognize the Crotalus and Lachesis genera, indicating specificity for the Bothrops genus. Through in vitro tests, the capacity to neutralize the toxicity triggered by BjussuMP‐II was observed. Circular dichroism spectroscopy indicated a robust secondary structure for VHH61, and the calculated melting temperature (TM) for the clone was 56.4°C. In silico analysis, through molecular docking of anti‐BjussuMP‐II VHHs with metalloprotease, revealed their potential interaction with amino acids present in regions critical for the toxin’s conformation and stability. The findings suggest that anti‐BjussuMP‐II VHHs may be beneficial in the development of next‐generation antivenoms.

24 October 2019 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JSJ.C. Sobrinho
J.C. Sobrinho
AFA.F. Francisco
A.F. Francisco
RSR. Simões-Silva
R. Simões-Silva
AKA.M. Kayano
A.M. Kayano
JAJorge Javier Alfonso
Jorge Javier Alfonso
ASAndreimar Soares
Andreimar Soares
Background: Several studies have aimed to identify molecules that inhibit the toxic actions of snake venom phospholipases A2 (PLA2s). Studies carried out with PLA2 inhibitors (PLIs) have been shown to be efficient in this assignment. Objective: This work aimed to analyze the interaction of peptides derived from Bothrops atrox PLIγ (atPLIγ) with a PLA2 and to evaluate the ability of these peptides to reduce phospholipase and myotoxic activities. Methods: Peptides were subjected to molecular docking with a homologous Lys49 PLA2 from B. atrox venom modeled by homology. Phospholipase activity neutralization assay was performed with BthTX-II and different ratios of the peptides. A catalytically active and an inactive PLA2 were purified from the B. atrox venom and used together in the in vitro myotoxic activity neutralization experiments with the peptides. Results: The peptides interacted with amino acids near the PLA2 hydrophobic channel and the loop that would be bound to calcium in Asp49 PLA2. They were able to reduce phospholipase activity and peptides DFCHNV and ATHEE reached the highest reduction levels, being these two peptides the best that also interacted in the in silico experiments. The peptides reduced the myotubes cell damage with a highlight for the DFCHNV peptide, which reduced by about 65%. It has been suggested that myotoxic activity reduction is related to the sites occupied in the PLA2 structure, which could corroborate the results observed in molecular docking. Conclusion: This study should contribute to the investigation of the potential of PLIs to inhibit the toxic effects of PLA2s.

1 January 2025 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
JMJamile Mariano Macedo
Jamile Mariano Macedo
MSMateus Farias Souza
Mateus Farias Souza
ALAnderson de Lima
Anderson de Lima
AFAleff Ferreira Francisco
Aleff Ferreira Francisco
AKAnderson Makoto Kayano
Anderson Makoto Kayano
ASAndreimar Soares
Andreimar Soares
Background: Leishmaniasis is a neglected disease that mainly affects impoverished populations and receives limited attention from governments and research institutions. Current treatments are based on antimonial therapies, which present high toxicity and cause significant side effects, such as cardiotoxicity and hepatotoxicity. This study proposes using crotapotin, isolated from Crotalus durissus terrificus venom, as a potential inhibitor of the enzyme trypanothione reductase from Leishmania braziliensis (LbTR). Methods: In silico assays were conducted to evaluate the interaction of crotapotin with LbTR using molecular docking and molecular dynamics techniques. Recombinant LbTR was expressed in E. coli, and its enzymatic activity was confirmed. The inhibitory action of crotapotin on LbTR was then tested in enzymatic assays. Results: The stability of these interactions was confirmed over 200 ns molecular dynamics simulations, with a clustering analysis using the GROMACS method revealing a total of 12 distinct clusters. The five most representative clusters showed low RMSD values, indicating high structural stability of the LbTR-crotapotin complex. In particular, cluster 1, with 3,398 frames and an average RMSD of 0.189 nm from the centroid, suggests a dominant stable conformation of the complex. Additional clusters maintained average RMSD values between 0.173 nm and 0.193 nm, further reinforcing the robustness of the complex under physiological conditions. Recombinant LbTR expression was successful, yielding 4.8 mg/L with high purity, as verified by SDS-PAGE. In the enzymatic assays, crotapotin partially inhibited LbTR activity, with an IC50 of 223.4 μM. Conclusion: The in silico findings suggest a stable and structured interaction between crotapotin and LbTR, with low structural fluctuation, although the inhibition observed in in vitro assays was moderate. These results indicate the potential of crotapotin as a promising basis for developing specific LbTR inhibitors, contributing to the bioprospecting of new antiparasitic agents.

1 January 2025 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
JAJorge Javier Alfonso
Jorge Javier Alfonso
AGAna Fidelina Gómez Garay
Ana Fidelina Gómez Garay
AKAnderson Makoto Kayano
Anderson Makoto Kayano
RHRudson Holanda
Rudson Holanda
AFAleff Ferreira Francisco
Aleff Ferreira Francisco
LCLeonardo Calderon
Leonardo Calderon
Background: Chagas disease (CD), caused by Trypanosoma cruzi, affects approximately seven million individuals worldwide, with the highest number of cases in Latin America. CD has two phases, of which the chronic phase is characterized by reduced efficacy in drug therapies. This and other factors make developing new strategies that aim to identify molecules capable of becoming alternatives to or complement current chemotherapy vitally important.

1 January 2022 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
JMJeane Do Nascimento Moraes
Jeane Do Nascimento Moraes
AFAleff Ferreira Francisco
Aleff Ferreira Francisco
LDLeandro Moreira Dill
Leandro Moreira Dill
RDRafaela Souza Diniz
Rafaela Souza Diniz
COClaudia Siqueira de Oliveira
Claudia Siqueira de Oliveira
LCLeonardo Calderon
Leonardo Calderon
Cathepsin D (CatD) is a lysosomal proteolytic enzyme expressed in almost all tissues and organs. This protease is a multifunctional enzyme responsible for essential biological processes such as cell cycle regulation, differentiation, migration, tissue remodeling, neuronal growth, ovulation, and apoptosis. The overexpression and hypersecretion of CatD have been correlated with cancer aggressiveness and tumor progression, stimulating cancer cell proliferation, fibroblast growth, and angiogenesis. In addition, some studies report its participation in neurodegenerative diseases and inflammatory processes. In this regard, the search for new inhibitors from natural products could be an alternative against the harmful effects of this enzyme. An investigation was carried out to analyze CatD interaction with snake venom toxins in an attempt to find inhibitory molecules. Interestingly, human CatD shows the ability to bind strongly to snake venom phospholipases A2 (svPLA2), forming a stable muti-enzymatic complex that maintains the catalytic activity of both CatD and PLA2. In addition, this complex remains active even under exposure to the specific inhibitor pepstatin A. Furthermore, the complex formation between CatD and svPLA2 was evidenced by surface plasmon resonance (SPR), two-dimensional electrophoresis, enzymatic assays, and extensive molecular docking and dynamics techniques. The present study suggests the versatility of human CatD and svPLA2, showing that these enzymes can form a fully functional new enzymatic complex.